Global expert panel issues first consensus roadmap for brentuximab vedotin nerve damage
Brentuximab vedotin has transformed the outlook for patients with CD30-positive lymphomas, but the antibody-drug conjugate carries a neurological price that ...
Brentuximab vedotin has transformed the outlook for patients with CD30-positive lymphomas, but the antibody-drug conjugate carries a neurological price that ...
A new review argues that B7-H3 positivity measured by immunohistochemistry is necessary but not sufficient to predict response to antibody-drug ...
A rare but serious infusion accident has been documented for the first time in the medical literature. Urologists at University ...
New research links the secreted glycoprotein LGALS3BP to selective enrichment of microRNAs and the RNA-binding protein SRSF1 in neuroblastoma extracellular ...
A multicenter real-world study found that first-line trastuzumab deruxtecan doubled progression-free survival compared with chemotherapy in HER2-altered advanced NSCLC, while ...
A novel CDH17-targeted antibody-drug conjugate called SCR-A008 achieved sustained tumor inhibition in gastric cancer PDX models, with a paclitaxel combination ...
A real-world cohort of 126 Chinese patients shows trastuzumab deruxtecan delivers a median 9.1 months of progression-free survival in HER2-low ...
A multicenter Central European real-world study finds sacituzumab govitecan delivers meaningful survival benefit and manageable toxicity in heavily pretreated metastatic ...
Researchers at the University of California San Diego School of Medicine have announced a pioneering therapeutic strategy aimed specifically at ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.